Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Veru inc. symbols : Lly save search
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.21%
H: 0.11%
C: -1.06%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.9%
H: 2.03%
C: 1.89%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: -0.53%
H: 2.22%
C: -3.59%
ALT | $7.095 -6.28% -6.69% 2.2M
|
Commercial Services
|
| O: 0.3%
H: 11.41%
C: 9.8%
medical program
Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasing Fat Loss in a Phase 2b Obesity Clinical Study
Published: 2023-10-04 (Crawled : 13:00) - globenewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 1.88%
H: 0.59%
C: -0.44%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -2.39%
H: 0.0%
C: 0.0%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: 6.22%
H: 1.26%
C: -6.19%
ozempic obesity study
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)
Published: 2023-09-26 (Crawled : 13:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: 5.69%
H: 3.37%
C: -10.11%
fda sabizabulin respiratory trial agreement
Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023
Published: 2023-09-20 (Crawled : 13:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.21%
H: 0.0%
C: 0.0%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: 1.63%
H: 11.9%
C: 9.23%
conference global
Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer
Published: 2023-09-11 (Crawled : 11:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 2.42%
H: 0.0%
C: 0.0%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: 1.45%
H: 0.95%
C: 0.0%
breast cancer her2- study
Veru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023
Published: 2023-08-30 (Crawled : 12:30) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.18%
H: 0.49%
C: -1.26%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: 0.0%
H: 2.8%
C: 2.8%
conference global
Veru Reports Fiscal 2023 Third Quarter Financial Results
Published: 2023-08-10 (Crawled : 11:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.81%
H: 1.01%
C: -0.41%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: 0.93%
H: 1.83%
C: 0.0%
financial results
Veru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023
Published: 2023-08-03 (Crawled : 12:20) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: -0.85%
H: 3.45%
C: 0.86%
report financial results
Prostate Cancer Global Market to Witness Upsurge in Growth at a CAGR of ~5% by 2028 | DelveInsight
Published: 2023-07-05 (Crawled : 21:00) - prnewswire.com
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 0.86%
H: 0.0%
C: -1.01%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -1.17%
H: 0.63%
C: 0.22%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.55%
H: 0.97%
C: 0.02%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: -6.72%
OPK | $1.225 -2.0% -2.04% 6.1M
|
Health Technology
|
| O: -1.19%
H: 1.2%
C: -0.72%
ADXS | $0.54 12.48% 950
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -6.83%
cancer global growth market
Veru Inc.’s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal Grants
Published: 2023-06-21 (Crawled : 12:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.56%
H: 0.18%
C: -0.33%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: -1.63%
drug health research program grants
Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board
Published: 2023-06-01 (Crawled : 12:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.19%
H: 1.52%
C: 1.45%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: 1.01%
H: 3.5%
C: -2.41%
disease
Veru to Present at the Jefferies Healthcare Conference
Published: 2023-05-24 (Crawled : 12:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.19%
H: 1.17%
C: 0.42%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: -0.93%
H: 1.87%
C: -0.93%
conference
Veru Reports Fiscal 2023 Second Quarter Financial Results
Published: 2023-05-11 (Crawled : 11:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.18%
H: 0.03%
C: -0.26%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: 1.34%
H: 0.0%
C: -18.54%
financial results
Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS
Published: 2023-05-04 (Crawled : 12:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.06%
H: 0.29%
C: -0.7%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: 0.0%
H: 2.36%
C: 0.0%
covid-19 fda sabizabulin treatment risk trial agreement
Veru Enters into Common Stock Purchase Agreement for Up to $100 Million with Lincoln Park Capital
Published: 2023-05-03 (Crawled : 12:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 2.68%
H: 4.62%
C: 3.89%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: -2.38%
H: 6.93%
C: 3.25%
agreement
Veru to Report Fiscal 2023 Second Quarter Financial Results on May 11, 2023
Published: 2023-04-27 (Crawled : 11:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 3.98%
H: 1.86%
C: -0.23%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: 3.13%
H: 0.0%
C: -3.79%
report financial results
Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset
Published: 2023-04-20 (Crawled : 12:20) - biospace.com/
BWV | $0.1802 5.44% 530K
|
|
| O: 1.51%
H: 2.73%
C: -2.73%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.25%
H: 1.26%
C: 0.92%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: 2.91%
H: 16.04%
C: 13.21%
entadfi water acquisition blue
Veru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones
Published: 2023-04-20 (Crawled : 11:00) - globenewswire.com
BWV | $0.1802 5.44% 530K
|
|
| O: 1.51%
H: 2.73%
C: -2.73%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.25%
H: 1.26%
C: 0.92%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: 2.91%
H: 16.04%
C: 13.21%
entadfi sales business plus
Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom® in U.S. Public Health Sector
Published: 2023-04-19 (Crawled : 13:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.17%
H: 0.2%
C: -0.02%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: -1.94%
H: 4.95%
C: 1.98%
condom health agreement
Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses
Published: 2023-04-11 (Crawled : 14:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.21%
H: 0.28%
C: -1.01%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: 0.0%
H: 9.0%
C: 1.0%
sabizabulin preclinical results study
Gainers vs Losers
| 63% | 37% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.